Meeting
2014 Genitourinary Cancers Symposium
Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium.
Authors
Won Kim
University of California, San Francisco, San Francisco, CA
Won Kim , John Wilton , Li Zhang , Amy M. Lin , Lawrence Fong , Terence W. Friedlander , Andrew Caleb Hsieh , Rahul Raj Aggarwal , Tammy J. Rodvelt , Allison Morse , Jeffrey Bozeman , Vivian K. Weinberg , Arturo Molina , James Mohler , Gerald J. Fetterly , Russell Zelig Szmulewitz , Eric Jay Small , Charles J. Ryan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01199146
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 53)
DOI
10.1200/jco.2014.32.4_suppl.53
Abstract #
53
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Mary-Ellen Taplin
Poster
2014 Genitourinary Cancers Symposium
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
First Author: Bobby Chi-Hung Liaw
Poster
2014 Genitourinary Cancers Symposium
Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients.
First Author: M. Andreas Roeder
Poster
2012 Genitourinary Cancers Symposium
Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
First Author: Ignacio Gil-Bazo